A vs. ELAN: Agilent vs. Elanco Animal Health Stock Comparison
How do Agilent (A) and Elanco Animal Health (ELAN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Agilent (A) and Elanco Animal Health (ELAN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while ELAN is classified in Pharmaceuticals.
| Profile Item | A | ELAN |
|---|---|---|
| Name | AgileThought, Inc. Class A Common Stock | Elanco Animal Health Incorporated |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 49.28 billion USD | 12.86 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | November 18, 1999 | September 20, 2018 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | A | ELAN |
|---|---|---|
| Total Return (1Y) | 22.92% | 24.03% |
| Total Return (3Y, Annualized) | 19.33% | 37.47% |
| Total Return (5Y, Annualized) | 3.03% | -4.24% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | A | ELAN |
|---|---|---|
| Volatility (1Y, Annualized) | 33.10% | 43.57% |
| Beta (5Y) | 1.22 | 1.65 |
| Max Drawdown (5Y) | -38.09% | -75.59% |
| Avg. Volume (3M) | 2.25M | 5.65M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | A | ELAN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.56 | 0.45 |
| Sortino Ratio (1Y) | 0.96 | 0.66 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Agilent (A) earns 20.97% on shareholders’ equity, ranked against its industry; Elanco Animal Health (ELAN) has no ROE this period.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.97%
- Max
- 109.18%
- A
- 20.97%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ELAN
- --
Net Margin (TTM)
Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Agilent (A) reports 19.53%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.53%
- A
- 19.53%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-2.86%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- ELAN
- -2.86%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Agilent (A) at 25.56% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.56%
- Max
- 83.12%
- A
- 25.56%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64%
- Max
- 83.12%
- Q3
- 14.77%
- ELAN
- 6.64%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | A | ELAN |
|---|---|---|
| ROE (TTM) | 20.97% | -- |
| ROA (TTM) | 8.63% | -- |
| Net Margin (TTM) | 19.53% | -2.86% |
| Operating Margin (TTM) | 25.56% | 6.64% |
| Gross Margin (TTM) | 53.65% | 56.18% |
Growth
Revenue Growth
Both Agilent (A) at 6.73% and Elanco Animal Health (ELAN) at 6.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Agilent (A) at 3.16% is around its peer norm for EPS growth, while Elanco Animal Health (ELAN) at -169.12% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | A | ELAN |
|---|---|---|
| Revenue Growth (YoY) | 6.73% | 6.22% |
| Revenue Growth (3Y CAGR) | 0.48% | 2.25% |
| EPS Growth (YoY) | 3.16% | -169.12% |
| EPS Growth (3Y CAGR) | 3.02% | -- |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Agilent (A) shows current ratio of 2.05 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.05
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- A
- 2.05
- Min
- 0.10
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ELAN
- --
Debt / Equity (MRQ)
Both Agilent (A) at 0.56 and Elanco Animal Health (ELAN) at 0.64 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.56
- Max
- 1.42
- Q3
- 0.65
- A
- 0.56
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.64
- Max
- 1.42
- Q3
- 0.65
- ELAN
- 0.64
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | A | ELAN |
|---|---|---|
| Current Ratio (MRQ) | 2.05 | -- |
| Debt / Equity (MRQ) | 0.56 | 0.64 |
| Net Debt / EBITDA | 1.15 | 3.49 |
Dividends
Dividend Yield (TTM)
Elanco Animal Health (ELAN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.59%
- A
- 0.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Elanco Animal Health (ELAN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.98%
- A
- 19.98%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | A | ELAN |
|---|---|---|
| Dividend Yield (TTM) | 0.59% | 0.00% |
| Dividend Payout Ratio (TTM) | 19.98% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Agilent (A) trades at 34.47 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.47
- Max
- 85.34
- Q3
- 43.46
- A
- 34.47
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ELAN
- --
P/S Ratio (TTM)
Elanco Animal Health (ELAN) at 2.50 sits in the cheaper P/S ratio quartile while Agilent (A) at 6.68 prices around its industry’s middle — ELAN costs less per dollar of sales, though read it alongside growth and margins.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- A
- 6.68
- Q1
- 3.01
- Min
- 0.01
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ELAN
- 2.50
- Min
- 0.01
P/B Ratio (MRQ)
Elanco Animal Health (ELAN) at 1.95 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 13.53
- A
- 6.69
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- ELAN
- 1.95
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | A | ELAN |
|---|---|---|
| P/E Ratio (TTM) | 34.47 | -- |
| P/S Ratio (TTM) | 6.68 | 2.50 |
| P/B Ratio (MRQ) | 6.69 | 1.95 |
| Free Cash Flow Yield (TTM) | 2.15% | -- |